Patents by Inventor Philip D. Ramsden

Philip D. Ramsden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME
    Publication number: 20250074895
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: November 19, 2022
    Publication date: March 6, 2025
    Inventors: Richard Vargas, Emanuele Perola, Philip D. Ramsden, Steven Mark Wenglowsky, Douglas Wilson
  • CDK2 INHIBITORS
    Publication number: 20240383902
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: March 14, 2024
    Publication date: November 21, 2024
    Inventors: Douglas Wilson, Neil Bifulco, JR., Natasja Brooijmans, Joseph L. Kim, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • SUBSTITUTED PYRIMIDINYL-PYRAZOLES AS CDK2 INHIBITORS
    Publication number: 20240287040
    Abstract: The present disclosure provides a compound represented by structural formula (I): (I), or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 15, 2022
    Publication date: August 29, 2024
    Inventors: Philip D. Ramsden, Neil Bifulco, Jr., Natasja Brooijmans, Emanuele Perola, Richard Vargas, Steven Mark Wenglowsky, Douglas Wilson
  • CDK2 inhibitors
    Patent number: 11970498
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: February 8, 2023
    Date of Patent: April 30, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • CDK2 inhibitors
    Patent number: 11932648
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: March 19, 2024
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • CDK2 INHIBITORS
    Publication number: 20230322791
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: February 8, 2023
    Publication date: October 12, 2023
    Inventors: Douglas Wilson, Neil Bifulco, JR., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky
  • CDK2 INHIBITORS
    Publication number: 20230159535
    Abstract: The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: June 27, 2022
    Publication date: May 25, 2023
    Inventors: Douglas Wilson, Neil Bifulco, Jr., Natasja Brooijmans, Joseph L. Kim, Emanuele Perola, Philip D. Ramsden, Richard Vargas, Steven Mark Wenglowsky